Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals

被引：0
|
作者：
Jagpreet Chhatwal
Tianhua He
Maria A. Lopez-Olivo
机构：
[1] Harvard Medical School,Institute for Technology Assessment, Massachusetts General Hospital
[2] Tsinghua University School of Medicine,Department of General Internal Medicine
[3] The University of Texas,undefined
[4] MD Anderson Cancer Center,undefined
来源：
PharmacoEconomics | 2016年 / 34卷
关键词：
Sustained Virological Response Rate; Telaprevir; Sofosbuvir; Boceprevir; Consolidate Health Economic Evaluation Reporting Standard;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：551 / 567
页数：16
相关论文
共 50 条
  • [21] Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)
    Peiffer, Kai-Henrik
    Zeuzem, Stefan
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2022, 65 (02) : 246 - 253
  • [22] Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C
    Juanbeltz, R.
    Zozaya, J. M.
    Reparaz, J.
    Castilla, J.
    Sarobe, M. T.
    Otano, J. I. Uriz
    de Alda, M. Gracia Ruiz
    Miguel, R. San
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2017, 40 (01) : 57 - 66
  • [23] Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
    Chae, Hee Bok
    Park, Seon Mee
    Youn, Sei Jin
    SCIENTIFIC WORLD JOURNAL, 2013,
  • [24] A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease
    Maruyama, Anna
    Partovi, Nilufar
    Yoshida, Eric M.
    Erb, Siegfried R.
    Azalgara, Vladimir Marquez
    Hussaini, Trana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (01) : 35 - 41
  • [25] Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
    Xiao, Fei
    Fofana, Isabel
    Thumann, Christine
    Mailly, Laurent
    Alles, Roxane
    Robinet, Eric
    Meyer, Nicolas
    Schaeffer, Mickael
    Habersetzer, Francois
    Doffoel, Michel
    Leyssen, Pieter
    Neyts, Johan
    Zeisel, Mirjam B.
    Baumert, Thomas F.
    GUT, 2015, 64 (03) : 483 - +
  • [26] The changing face of hepatitis C in the new era of direct-acting antivirals
    Soriano, Vincent
    Labarga, Pablo
    Fernandez-Montero, Jose V.
    Benito, Jose M.
    Poveda, Eva
    Rallon, Norma
    Sanchez, Clara
    Vispo, Eugenia
    Barreiro, Pablo
    ANTIVIRAL RESEARCH, 2013, 97 (01) : 36 - 40
  • [27] Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong
    Li, X.
    Chan, N. S.
    Tam, A. W.
    Hung, I. F. N.
    Chan, E. W.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2017, 36 (10) : 1801 - 1809
  • [28] Emerging Therapies in Hepatitis C: Dawn of the Era of the Direct-Acting Antivirals
    Jazwinski, Alison B.
    Muir, Andrew J.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2011, 40 (03) : 481 - +
  • [29] Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients
    Burgess, Sarah
    Partovi, Nilufar
    Yoshida, Eric M.
    Erb, Siegfried R.
    Azalgara, Vladimir Marquez
    Hussaini, Trana
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (06) : 674 - 687
  • [30] Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
    Gallach, Marta
    Vergara, Mercedes
    Pedro da Costa, Joao
    Miquel, Mireia
    Casas, Meritxell
    Sanchez-Delgado, Jordi
    Dalmau, Blai
    Rudi, Nuria
    Parra, Isabel
    Monllor, Teresa
    Sanchez-Lloansi, Meritxell
    Dosal, Angelina
    Valero, Oliver
    Calvet, Xavier
    PLOS ONE, 2018, 13 (12):
12345